The burden of cancer worldwide, according to the global cancer incidence, mortality and prevalence report (GLOBOCAN 2018) \[[@B1]\], estimated that in 2018 there were 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer). In addition, in both men and women combined, lung cancer was the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths). Other types of cancer with the highest mortality rates are female breast cancer (11.6%), colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%). Of note, lung cancer was the most frequent cancer and the leading cause of cancer death among males, followed by liver and stomach cancer. On the other hand, in women, breast cancer was the most commonly diagnosed cancer as well as the leading cause of cancer death, followed by lung and colorectal cancer. Interestingly, cervical cancer ranks fourth for mortality \[[@B1],[@B2]\]

Early detection and diagnosis of cancer can lead to timely therapeutic/surgical interventions that can increase the chances of survival. Despite intense research and discovery over the years of many candidate biomarkers for cancer screening, only a few have transitioned to routine usage in the clinic \[[@B3]\]. Promising candidates that are in the discovery and developmental mode include circulating tumor cells and cell-free tumor DNA \[[@B4],[@B5]\], miRNAs \[[@B6],[@B7]\], secretome of the gut microbiota \[[@B8]\], exhaled volatile organic compounds, proteomics and metabolomics (liquid biopsy) \[[@B9]\]. These face many challenges before routine implementation in the clinical setting \[[@B11],[@B12]\]. In order to introduce a general cancer screening test into practice, the cost and access are important factors that need to be taken into account. Development of a simple, clinically viable, economical, accurate and reproducible screening test would be highly beneficial for the at-risk population.

Polyamines are intimately involved in cell growth, proliferation and cell death \[[@B13],[@B14]\]. Spermidine/spermine N^1^-acetyltransferase-1 (SSAT-1) is a key enzyme in the polyamine metabolic pathway and is known to be upregulated in cancer \[[@B15]\]. Amantadine, which is a US FDA-approved antiviral drug and anti-Parkinson's medication, is a specific substrate of SSAT-1. Amantadine is acetylated by SSAT-1 to produce acetylamantadine (AA) \[[@B18]\], which is a stable end product excreted in urine \[[@B18],[@B19]\]. We have reported the clinical utility of amantadine to detect elevated SSAT-1 activity by measuring increased concentration of AA in the urine of cancer patients \[[@B20],[@B21]\]. In earlier studies, a proportion of the healthy adult controls were deemed to be 'outliers' because of higher than expected AA concentrations in the urine. Accordingly, the present study was undertaken to further investigate the outlier group by: performing a follow-up amantadine test; conducting thorough clinical and hematological assessments; and conducting a follow-up health status questionnaire and accessing electronic medical records of these individuals.

Materials & methods {#S0001}
===================

Regulatory & institutional review board approvals {#S0002}
-------------------------------------------------

Ethics approval was obtained from the University of Manitoba Biomedical Research Ethics Board (Ethics File \#s: B2012:063 and B2011:073) prior to study implementation. The study protocol was reviewed and approved by Health Canada (File \# 9427-B2749-21C): Notice of Authorization was dated 17 July 2012 and was also listed on the NIH [Clinicaltrials.gov](http://Clinicaltrials.gov) website (Identifier: NCT02277938). Appropriate Institutional Review Board (Ministry of Health & Family Welfare, the People's Republic of Bangladesh) approvals were also obtained (Ethics File \# NICRH/Ethics/2017/288). Clinical studies were completed under GCP and GLP conditions in accordance with the standards established by the Canadian Tri-Council Policies.

Experimental subjects {#S0003}
=====================

Healthy controls (n = 40) were recruited by the National Institute of Cancer Research & Hospital, Department of Medical Oncology, Mohakhali, Dhaka, Bangladesh within the local area as part of a study that was being conducted to investigate urinary AA levels in cancer patients \[[@B21]\]. 20 healthy adult controls were also recruited locally at the Asper Clinical Research Institute, St Boniface Hospital, Winnipeg, Canada. All participants provided a signed informed consent for participation. Inclusion criteria were volunteers aged between 18 and 80 years with no history of liver or kidney disease; exclusion criteria were alcohol consumption within 5 days of amantadine ingestion, previous adverse reaction to amantadine and currently pregnant or lactating females. At time of recruitment and participation in the study, none of the healthy control volunteers reported a diagnosis of cancer. After overnight fasting, participants were requested to provide a complete urine collection on the day of the study prior to ingesting amantadine. They then ingested orally 200 mg (2 × 100 mg) amantadine capsules (Mylan-Amantadine, amantadine hydrochloride, USP). Urine was then collected at 2, 4 and 6 h postamantadine ingestion for analysis as previously described \[[@B20],[@B21]\]. Participants that were deemed as outliers were consented for follow-up after obtaining appropriate approvals from the respective institutional review boards.

Analytical procedures & data cross-validation {#S0004}
=============================================

Urine was analyzed for AA by established and validated GLP-compliant LC--MS/MS methods using d~3~-AA as the internal standard for quantitation at Biopharmaceuticals Research Inc. (BC, Canada; Study \#: BIM-2015-001). Health Canada authorized Biomark AA assay standard under application no: 229838 on 7 October 2014 (Investigational Testing Authorization). The measurement of urinary concentration of AA was conducted as previously described \[[@B20],[@B21]\], Data were cross-validated as described elsewhere \[[@B22],[@B23]\]. The study staff coded the samples and the technician analyzing the biological samples was blinded to participant information.

Blood analyses & other clinical assessments {#S0005}
===========================================

Hematological tests, mammogram and ultrasound were conducted using standard procedures at the National Institute of Cancer Research & Hospital, Dhaka, Bangladesh. Serum CEA was measured at Life Labs (ON, Canada) by immunoassay.

Statistical analysis {#S0006}
====================

Microcal Origin 6 software was used for the calculation of mean values and standard error of the mean (SEM). Box plots were constructed using GraphPad Prism 8.1.

Results {#S0007}
=======

Healthy control & cancer patient characteristics {#S0008}
------------------------------------------------

The demographic information of each of the healthy adult participants is shown in [Table 1](#T1){ref-type="table"} (Bangladesh site) and [Table 2](#T2){ref-type="table"} (Winnipeg site). The mean age (±SEM) of the healthy group at the Bangladesh site (n = 40; 20 male, 20 female) was 52 ± 2 years, whereas the mean age (±SEM) of the healthy group at the Winnipeg site (n = 20; 9 male, 11 female) was 38 ± 3 years. In the Bangladesh cohort, 11/40 (27%) and 2/40 (5%) participants were considered to be overweight (body mass index \[BMI\] = 25.0--29.9) and obese (BMI ≥30.0), respectively. In the Winnipeg cohort, 10/20 (50%) and 3/20 (15%) were considered to be overweight (BMI = 25.0--29.9) and obese (BMI≥ 30.0), respectively. On the other hand, 6/40 (15%) subjects in the Bangladesh healthy group were deemed to be underweight (BMI \<18.5), while only one participant (5%) in the Winnipeg healthy group was determined to be underweight.

###### Demographic information on healthy adult volunteers recruited locally at Dhaka (Bangladesh site).

  Subject ID   Age (years)   Height (ft; inch)   Weight (lbs)   BMI (kg/m^2^)   Sex (M/F)   Subject ID   Age (years)   Height (ft; inch)   Weight (lbs)   BMI sex (kg/m^2^; M/F)
  ------------ ------------- ------------------- -------------- --------------- ----------- ------------ ------------- ------------------- -------------- ------------------------
  H01          50            5'5"                132.2          22.0            M           H21          54            5'1"                134.5          25.4 F
  H02          27            5'2"                119.1          21.8            F           H22          51            4'11"               119.1          24.1 F
  H03          44            4'10"               141.1          29.5            F           H23          55            5'0"                90.4           17.7 F
  H04          46            5'2"                156.5          28.6            F           H24          58            5'6"                127.7          20.6 M
  H05          43            5'3"                154.3          27.3            F           H25          56            5'6"                132.3          21.4 M
  H06          50            5'6"                110.2          17.8            M           H26          57            5'5"                160.9          26.8 M
  H07          42            5'11"               178.6          24.9            M           H27          52            5'2"                143.3          26.2 F
  H08          29            5'2"                121.3          22.2            F           H28          42            5'1"                152.1          28.7 F
  H09          37            5'1"                121.3          22.9            F           H29          52            4'11"               88.2           17.8 F
  H10          50            5'1"                108.0          20.4            F           H30          67            5'1"                81.6           15.4 F
  H11          56            4'11"               194.0          39.2            F           H31          58            5'5"                141.1          23.5 M
  H12          34            5'2"                114.6          21.0            F           H32          50            5'4"                138.9          23.8 M
  H13          53            5'3"                123.5          21.9            M           H33          55            5'7"                123.5          19.3 M
  H14          48            5'5"                143.3          23.8            M           H34          58            5'8"                152.1          23.1 M
  H15          46            5'3"                132.3          22.0            M           H35          59            5'5"                154.3          25.7 M
  H16          70            4'9"                121.3          26.3            F           H36          55            5'6"                154.3          24.9 M
  H17          38            5'0"                138.9          27.1            F           H37          62            5'8"                138.9          21.1 M
  H18          52            4'11"               154.3          31.2            F           H38          55            5'7"                158.7          24.9 M
  H19          55            5'2"                83.8           15.3            M           H39          63            5'5"                138.9          23.1 M
  H20          75            4'10"               88.2           18.4            F           H40          61            5'4"                154.3          26.5 M

The BMI is defined according to \[[@B46]\]. BMI scale: \<18.5 underweight; 18.5--24.9 normal; 25.0--29.9 overweight; \>30.0 obese.

BMI: Body mass index; F: Female; M: Male; ' = Feet; " = Inches.

###### Demographic information on healthy adult volunteers recruited locally at the Asper Clinical Research Institute (Winnipeg site).

  Subject ID   Age (years)   BMI (kg/m2)   Weight (lbs)   BMI (kg/m^2^)   Sex (M/F)
  ------------ ------------- ------------- -------------- --------------- -----------
  BM0001       28            5'7"          136.5          22.0            F
  BM0002       24            5'5"          158.6          27.2            F
  BM0003       57            5'3"          164.2          29.1            F
  BM0004       34            5'7"          177.8          27.8            F
  BM0005       49            5'3"          132.0          23.4            F
  BM0006       46            5'5"          180.0          30.0            F
  BM0007       28            5'3"          158.4          28.1            F
  BM0008       49            5'3"          116.5          20.6            F
  BM0009       22            5'3"          144.0          25.5            F
  BM0010       63            5'3"          158.4          28.1            F
  BM0011       25            5'7"          115.7          18.1            F
  BM0021       50            5'9"          200.2          29.6            M
  BM0022       61            5'9"          181.2          26.8            M
  BM0023       51            6'0"          232.4          31.5            M
  BM0024       54            6'0"          203.8          27.6            M
  BM0025       23            5'5"          140.0          23.3            M
  BM0026       43            5'5"          157.0          26.1            M
  BM0027       19            5'7"          141.6          22.2            M
  BM0028       18            5'8"          149.2          22.7            M
  BM0029       18            5'1"          178.4          33.7            M

The BMI is defined according to \[[@B46]\]. BMI scale: \<18.5 underweight; 18.5--24.9 normal; 25.0--29.9 overweight; \>30.0 obese.

BMI: Body mass index; F: Female; M: Male; ' = Feet; " = Inches.

Delineation of 'outliers' {#S0009}
-------------------------

[Figure 1](#F1){ref-type="fig"} shows the box plots statistical data with minimum, first quartile, median, third quartile and maximum for AA. Total AA mean excretion at 4 h (ng) in Winnipeg volunteers was 600 ng that provided a tighter assessment after extreme outlier were accounted for in isolating outliers. For the Bangladesh cohort, a 2000 ng at 6 h provided a better cutoff point in selection of outlier definition following management of extreme outliers.

![Box plot statistical data for total acetylamantadine amount in healthy volunteers at study sites.\
Data are presented for Bangladesh **(A & B)** and Winnipeg **(C)** healthy groups. Box plots were constructed to ascertain cutoff points in ostensibly normal individual's for determination of 'outliers' according to the amantadine test.](fsoa-05-400-g1){#F1}

### Urinary concentrations of AA in healthy adult volunteers (Bangladesh site) {#S0010}

Analysis of the urine samples revealed that in the Bangladesh site there, was a higher than expected concentration (≥24.0 ng/ml) or total amount (\>2000 ng) of AA at 6 h in 22/40 (50%) of the healthy adult volunteers ([Table 3](#T3){ref-type="table"}). The serum concentration of CEA was also determined in the 40 healthy adult volunteers. As shown in [Table 4](#T4){ref-type="table"}, 18/40 (45%) participants exhibited CEA concentration ≥2.5 ng/ml. However, 11/18 (61%) of the participants were considered outliers because of the overlapping between the results of the AA test combined with the CEA concentrations. An attempt to contact these 11 participants for a follow-up was made with seven favorable responders (H03, H07, H11, H12, H17, H18 and H26). The follow-up was conducted at 6 and 9 months after completion of the initial amantadine test. Interestingly, five out of seven (71%) participants showed an increase in the 2 h urinary AA concentration at 6 months ([Table 5](#T5){ref-type="table"}) as compared with the concentration observed with the initial amantadine test, which decreased at the 9-month follow-up to near initial values.

###### Urinary acetylamantadine concentration in healthy adult volunteers recruited locally at Dhaka (Bangladesh site).

  Subject ID                               2 h \[AA\] (ng/ml)   Urine (ml)   Total AA (ng)   4 h \[AA\] (ng/ml)   Urine (ml)   Total AA (ng)   6 h \[AA\] (ng/ml)   Urine (ml)   Total AA (ng)
  ---------------------------------------- -------------------- ------------ --------------- -------------------- ------------ --------------- -------------------- ------------ ---------------
  H01[^†^](#T3TFN1){ref-type="table-fn"}   25.4                 70           1778            24.4                 85           2074            58.2                 20           1164
  H02                                      20.1                 110          2211            10.8                 120          1296            16.9                 115          1944
  H03[^†^](#T3TFN1){ref-type="table-fn"}   11.9                 100          1190            165                  100          16,500          156                  55           8580
  H04[^†^](#T3TFN1){ref-type="table-fn"}   6.0                  80           478             65.3                 80           5224            32.1                 85           2729
  H05[^†^](#T3TFN1){ref-type="table-fn"}   49.5                 90           4455            83.3                 85           7081            178                  55           9790
  H06[^†^](#T3TFN1){ref-type="table-fn"}   10.5                 90           945             26.2                 70           1834            83.2                 65           5408
  H07[^†^](#T3TFN1){ref-type="table-fn"}   11.0                 85           935             29.1                 90           2619            66.4                 60           3984
  H08[^†^](#T3TFN1){ref-type="table-fn"}   24.7                 55           1359            37.6                 80           3008            34.3                 90           3087
  H09[^†^](#T3TFN1){ref-type="table-fn"}   42.0                 100          4200            42.0                 70           2940            40.6                 100          4060
  H10[^†^](#T3TFN1){ref-type="table-fn"}   11.6                 75           870             43.3                 60           2598            156                  50           7800
  H11[^†^](#T3TFN1){ref-type="table-fn"}   3.0                  130          384             185                  35           6475            45.1                 60           2706
  H12[^†^](#T3TFN1){ref-type="table-fn"}   31.4                 70           2198            132                  60           7920            91.3                 80           7304
  H13[^†^](#T3TFN1){ref-type="table-fn"}   6.4                  70           446             53.1                 65           3452            113                  60           6780
  H14                                      21.1                 80           1688            19.4                 100          1940            19.4                 75           1455
  H15                                      7.7                  90           697             10.5                 70           735             16.2                 75           1215
  H16                                      14.6                 95           1387            24.7                 80           1976            9.4                  65           614
  H17[^†^](#T3TFN1){ref-type="table-fn"}   9.8                  100          984             60.8                 100          6080            27.3                 90           2457
  H18[^†^](#T3TFN1){ref-type="table-fn"}   22.8                 100          2280            28.2                 90           2538            25.1                 90           2259
  H19                                      5.2                  120          623             18.0                 100          1800            8.1                  90           725
  H20                                      14.9                 90           1341            24.0                 110          2640            8.0                  120          959
  H21                                      9.0                  75           677             10.2                 80           816             4.7                  80           378
  H22                                      6.8                  60           408             30.9                 95           2934            5.2                  90           466
  H23                                      4.3                  60           256             7.1                  60           425             3.6                  80           284
  H24                                      7.5                  65           488             14.3                 100          1430            9.6                  75           722
  H25                                      12.8                 45           576             11.6                 40           464             2.8                  110          306
  H26[^†^](#T3TFN1){ref-type="table-fn"}   63.3                 90           5697            35.8                 75           2685            10.5                 200          2100
  H27                                      21.5                 90           1935            30.7                 50           1535            22.6                 55           1243
  H28                                      3.2                  80           254             80.6                 60           484             12.6                 115          1449
  H29                                      1.5                  110          164             6.1                  110          673             13.7                 105          1439
  H30[^†^](#T3TFN1){ref-type="table-fn"}   2.9                  70           204             13.8                 55           759             96                   30           2880
  H31[^†^](#T3TFN1){ref-type="table-fn"}   3.5                  120          414             14.7                 70           1029            34.6                 70           2422
  H32[^†^](#T3TFN1){ref-type="table-fn"}   18.0                 100          1800            14.5                 90           1305            42.5                 70           2975
  H33[^†^](#T3TFN1){ref-type="table-fn"}   6.3                  100          626             34.6                 70           2422            52.6                 80           4208
  H34                                      47.2                 100          4720            2.8                  80           227             7.2                  75           542
  H35                                      11.3                 110          1243            13.9                 110          1529            13.5                 100          1350
  H36                                      23.1                 100          2310            26.7                 105          2804            11.5                 100          1150
  H37                                      7.7                  80           617             13.7                 100          1370            15.2                 90           1368
  H38                                      1.6                  80           127             8.1                  75           609             5.6                  95           535
  H39[^†^](#T3TFN1){ref-type="table-fn"}   22.0                 80           1760            24.2                 100          2420            24.0                 95           2280
  H40                                      7.4                  105          781             19.2                 85           1632            11.20                85           286

Identified as an outlier based on total AA amount (ng) at 6 h time point of \>2000 ng or concentration of AA \>24.0 ng/ml.

AA: Acetylamantadine.

###### Serum concentrations of carcinoembryonic antigen in healthy adult volunteers recruited locally at Dhaka (Bangladesh site).

  Subject ID                               CEA (ng/ml)   Subject ID                               CEA (ng/ml)
  ---------------------------------------- ------------- ---------------------------------------- -------------
  H01[^†^](#T4TFN1){ref-type="table-fn"}   2.7           H21                                      1.9
  H02                                      1.8           H22                                      1.4
  H03[^†^](#T4TFN1){ref-type="table-fn"}   4.1           H23[^†^](#T4TFN1){ref-type="table-fn"}   4.5
  H04                                      0.5           H24                                      1.3
  H05                                      2.0           H25[^†^](#T4TFN1){ref-type="table-fn"}   4.5
  H06[^†^](#T4TFN1){ref-type="table-fn"}   3.3           H26[^†^](#T4TFN1){ref-type="table-fn"}   22.1
  H07[^†^](#T4TFN1){ref-type="table-fn"}   3.8           H27                                      2.3
  H08                                      1.0           H28                                      1.6
  H09                                      1.5           H29                                      2.0
  H10                                      1.7           H30[^†^](#T4TFN1){ref-type="table-fn"}   2.9
  H11[^†^](#T4TFN1){ref-type="table-fn"}   4.7           H31                                      1.2
  H12[^†^](#T4TFN1){ref-type="table-fn"}   3.4           H32                                      1.9
  H13[^†^](#T4TFN1){ref-type="table-fn"}   5.4           H33                                      1.7
  H14                                      1.6           H34[^†^](#T4TFN1){ref-type="table-fn"}   2.8
  H15                                      2.1           H35                                      1.8
  H16[^†^](#T4TFN1){ref-type="table-fn"}   3.9           H36                                      1.2
  H17[^†^](#T4TFN1){ref-type="table-fn"}   3.0           H37[^†^](#T4TFN1){ref-type="table-fn"}   2.5
  H18[^†^](#T4TFN1){ref-type="table-fn"}   6.1           H38                                      2.4
  H19                                      1.5           H39[^†^](#T4TFN1){ref-type="table-fn"}   3.1
  H20[^†^](#T4TFN1){ref-type="table-fn"}   2.8           H40                                      2.4

Identified as high CEA levels with ≥2.5 ng/ml as the cutoff.

###### Follow-up amantadine test in the outlier group at Dhaka (Bangladesh site).

  Subject ID   Initial   Follow-up 1   Follow-up 2                                      
  ------------ --------- ------------- ------------- ------ ------ ------ ------ ------ ------
  H03          11.9      165           156           21.0   30.3   41.4   11.4   113    30.9
  H07          11.0      29.1          66.4          28.4   60.2   64.7   1.7    33.4   19.5
  H11          3.0       185           45.1          7.1    36.3   77.2   1.5    45.2   67.3
  H12          31.4      132           91.3          92.6   81.5   46.5   46.1   120    54.9
  H17          9.8       60.8          27.3          39.4   71.2   42.3   6.7    25.0   48.3
  H18          22.8      28.2          25.1          17.5   74.9   103    5.9    19.7   9.3
  H26          14.9      24.0          8.0           6.8    46.9   21.5   1.8    14.3   26.4

Urinary AA concentrations were determined at 2, 4 and 6 h postamantadine ingestion at first follow-up (6 month) and at second follow-up (9-month) after the initial amantadine test.

AA: Acetylamantadine.

In order to understand the significance of the higher AA concentrations observed at the 6-month follow-up, a clinical assessment was conducted. In the two males in this follow-up cohort (H07 and H26), ultrasound revealed enlarged prostates with normal prostate-specific antigen values. With respect to the clinical features in the female outliers, mammogram revealed fibrotic changes in both breasts ([Table 6](#T6){ref-type="table"}). In addition, ultrasound also showed the presence of hepatomegaly and fatty changes in the liver in all seven individuals. Hematological assessments showed either elevated white blood cell count (H07 and H12) or elevated platelets (H11) or a platelet count in the upper range of normal (H17).

###### Clinical features of the healthy adult volunteer outlier group at Dhaka (Bangladesh site).

  Subject ID   Sex (M/F)   Age (years)   Mammogram/ultrasound                                                                                              Hematology (cells/μl)
  ------------ ----------- ------------- ----------------------------------------------------------------------------------------------------------------- ----------------------------------------
  H03          F           44            Enlarged axillary LN, mild fibrotic change in both breasts; mild hepatomegaly with fatty change; cholelithiasis   Normal
  H07          M           42            Mildly enlarged prostate (PSA normal); mild fatty change in liver                                                 Elevated WBC (15,000)
  H11          F           56            Mild fibrotic change in both breasts; mild hepatomegaly with fatty change                                         Elevated platelets (450,000)
  H12          F           34            Underlying mass lesion, dense breasts; mild fatty change in liver                                                 Elevated WBC (12,600)
  H17          F           38            Mild fibrotic change in both breasts; mild fatty change in liver                                                  High platelets (420,000), eosinophilia
  H18          F           52            Mild fibrotic change in both breasts; mild fatty change in liver                                                  Normal
  H26          M           57            Upper limit of normal prostate (PSA normal); mild hepatomegaly with fatty change                                  Normal

Normal range for WBCs, 4500--11,000 WBC/μl of blood; normal range for platelets 150,000--450,000 platelets per μl of blood.

F: Female; LN: Lymph node; M: Male; WBC: White blood cell.

### Urinary concentrations of AA in healthy adult volunteers (Winnipeg site) {#S0011}

We conducted a follow-up with the Winnipeg outliers within the healthy adult group. In this study, 11/20 (55%) participants were considered as outliers, in other words, having a higher than expected urinary concentration (≥6.0 ng/ml) or total amount (\>600 ng) of AA at 4 h ([Table 7](#T7){ref-type="table"}). These individuals were followed-up with a health questionnaire asking if they had experienced any health issue since completion of the study. On the basis of the responses to the questionnaire as well as accessing electronic medical records (CancerCare Manitoba), three of these outliers experienced some medical issue related to cancer, whereas one participant had registered with CancerCare Manitoba, but there was no diagnosis or clinical information available ([Table 8](#T8){ref-type="table"}).

###### Urinary acetylamantadine concentration in healthy adult volunteers recruited locally at Asper Clinical Research Institute (Winnipeg site).

  Subject ID                                  2 h \[AA\] (ng/ml)   Urine (ml)   Total AA (ng)   4 h \[AA\] (ng/ml)   Urine (ml)   Total AA (ng)   6 h \[AA\] (ng/ml)   Urine (ml)   Total AA (ng)
  ------------------------------------------- -------------------- ------------ --------------- -------------------- ------------ --------------- -------------------- ------------ ---------------
  BM0001                                      2.0                  220          429             2.2                  205          445             3.5                  130          452
  BM0002[^†^](#T7TFN1){ref-type="table-fn"}   10.5                 20           210             10.6                 40           424             10.7                 75           803
  BM0003[^†^](#T7TFN1){ref-type="table-fn"}   1.7                  180          297             3.4                  238          809             1.4                  228          309
  BM0004[^†^](#T7TFN1){ref-type="table-fn"}   1.1                  410          442             2.8                  320          880             4.5                  130          589
  BM0005[^†^](#T7TFN1){ref-type="table-fn"}   3.8                  40           152             3.2                  190          614             1.4                  180          252
  BM0006[^†^](#T7TFN1){ref-type="table-fn"}   1.2                  85           99              8.7                  145          1260            2.0                  165          333
  BM0007[^†^](#T7TFN1){ref-type="table-fn"}   3.0                  165          501             14.9                 120          1788            4.0                  175          707
  BM0008                                      1.6                  190          296             1.7                  205          344             5.0                  170          841
  BM0009[^†^](#T7TFN1){ref-type="table-fn"}   3.9                  170          660             9.2                  130          1191            5.8                  210          1210
  BM0010                                      1.1                  7            8               0.8                  120          99              0.4                  100          42
  BM0011[^†^](#T7TFN1){ref-type="table-fn"}   0.8                  410          314             3.2                  400          1288            1.7                  390          655
  BM0021[^†^](#T7TFN1){ref-type="table-fn"}   2.7                  220          603             9.3                  460          4264            5.3                  190          1005
  BM0022                                      2.3                  90           207             2.0                  95           194             2.1                  100          211
  BM0023                                      0.6                  315          201             3.3                  85           282             2.4                  155          369
  BM0024                                      4.4                  55           239             4.6                  90           413             4.4                  130          569
  BM0025                                      1.4                  50           69              4.0                  50           198             2.3                  100          229
  BM0026[^†^](#T7TFN1){ref-type="table-fn"}   0.6                  245          142             2.6                  305          790             3.5                  75           264
  BM0027                                      5.2                  160          837             4.4                  80           353             4.6                  130          593
  BM0028[^†^](#T7TFN1){ref-type="table-fn"}   3.8                  220          834             10.7                 100          1070            14.8                 115          1702
  BM0029                                      4.6                  120          550             5.8                  100          575             4.5                  140          631

Identified as an outlier based on total AA amount (ng) at 4 h time point of more than 600 ng or concentration of AA more than 6.0 ng/ml.

AA: Acetylamantadine.

###### Clinical features of the healthy adult volunteer outlier group at the Asper Clinical Research Institute (Winnipeg site).

  Subject ID   Sex (M/F)   Age (years)   Follow-up questionnaire/electronic medical records
  ------------ ----------- ------------- ---------------------------------------------------------------------------
  BM0021       M           50            No health issue
  BM0026       M           43            No health issue
  BM0028       M           18            No health issue
  BM0002       F           24            No health issue
  BM0003       F           57            Thyroid nodules (2013)
  BM0004       F           34            Ovarian cancer stage 1C (2014)
  BM0005       F           49            Lung nodules NYD (2016)
  BM0006       F           46            Registered with CCMB, but no diagnosis or information currently available
  BM0007       F           28            No health issue
  BM0009       F           22            No health issue
  BM0011       F           25            No health issue

CCMB: CancerCare Manitoba; NYD: Stage not yet determined.

Discussion {#S0012}
==========

We have recently reported that human cancer is associated with high urinary concentration of AA \[[@B20],[@B21]\] with receiver-operating characteristic (ROC) for AA demonstrated to be 0.689 (CI: 0.591--0.786, 95%) in lung cancer and 0.717 (CI: 0.577--0.858, 95%) for breast cancer \[[@B21]\]. In the present preliminary study, the initial data from Bangladesh healthy cohort had a high proportion of 'outliers' versus normal AA concentration at 6 h time point (\<24.0 ng/ml) or total amount of AA (\>2000 ng). Initial analysis of outliers demonstrated a large effect on the mean and median, which in turn affected the error (absolute and mean) in our dataset, and large deviations were observed when the error was plotted. Some of the outliers in Bangladesh had urinary AA concentrations that were between two- and six-times higher than the cutoff points, qualifying them as either intermediate or extreme outliers. This important deviation suggested that there could be valuable information to obtain and thus the 'outliers' were analyzed separately to try to understand the significance and clinical relevance of the higher AA concentrations. Also, in view of the small outlier sample size in both the Bangladesh versus Winnipeg cohorts it was not possible to conduct sensitivity analyses.

Since there was no apparent measurement or experimental design that would have led to exclusion of the outliers, we commissioned an assessment and follow-up to determine the health and qualification of status over a period of time. Accordingly, a thorough examination of the outliers at 6- and 9-month follow-up that entailed the amantadine test and comprehensive clinical and hematological assessments were conducted at the Bangladesh site. This leads to a follow-up study with the Winnipeg cohort, but this entailed a questionnaire as well as accessing electronic medical records; however, the 'outliers' in this cohort were outside of normal AA concentration (\<6.0 ng/ml) or total amount of more than 600 ng at the 4 h time point.

The follow-up analysis revealed that the amantadine test is possibly detecting cancer at a very early stage; therefore, it could be useful in screening populations at high risk for cancer. It should be noted that while a further increase in AA concentration in the 6-month follow-up compared with values in the first amantadine test was observed in some of Bangladesh outliers, a reduction in AA concentration at the 9-month follow-up was observed. These values were almost comparable to the AA concentration observed in the initial amantadine test. This biphasic nature of the AA concentrations are suggestive that the increase in AA serves as the trigger in the initiation of the processes involved in cell proliferation and growth, while the subsequent reduction in AA can be seen as an adaptive mechanism.

It should be mentioned that follow-up clinical assessment at the Bangladesh site, seven outliers had developed hepatomegaly and/or fatty liver. Hepatomegaly can occur as a consequence of infection, metabolic disorders, congestive heart failure or hepatic tumor \[[@B24]\]. Interestingly, high rates of liver cancer are known to occur in areas with high contamination levels of the carcinogen arsenic, such as in Bangladesh \[[@B27]\]. Indeed most of the participants recruited into the study as healthy subjects resided in areas with moderate to severe arsenic contamination \[[@B30]\] (based on recorded area of residence on screening forms \[data not shown\]). Furthermore, individuals with severe fatty liver (non-alcoholic fatty liver disease) need to be monitored for liver cancer because of the link between fatty liver disease and liver cancer (hepatocellular carcinoma) \[[@B31],[@B32]\]. It is pointed out that the connection between arsenic and cancer has been studied in some regions of Chile, where arsenic contamination is considered to be the primary cause of mortality due to lung cancer that is more than threefold as compared with noncontaminated areas in the same country \[[@B33]\].

While elevated white blood cell count is indicative of an infection, it has also been linked to other inflammations and in particular cancers gastric, lung and blood cancers \[[@B34]\]. Two of the outliers (H11 and H17) showed an elevated platelet count and eosinophilia, respectively. Eosinophilia has been linked to a wide variety of non-neoplastic disorders, as well as to neoplastic conditions \[[@B37]\] and an elevation in eosinophils may exert protumor effects \[[@B38],[@B39]\]. On the other hand, inflammation and platelet activation at the site of tissue damage is known to contribute to initiate a cascade of events, which promote tumorigenesis \[[@B40]\]. In fact, platelets release a wide variety of proteins, including growth and angiogenic factors, lipids, and extracellular vesicles rich in genetic material, which can mediate the induction of phenotypic changes in cancer cells, promoting carcinogenesis and metastasis \[[@B40]\].

Although being underweight has been linked to an increase in the risk of adverse health complications, overweight/obesity increases the risk of developing several cancers \[[@B41]\]. With respect to our observations, five outliers in the Bangladesh healthy group that had some pathophysiological indication of presymptomatic cancer ([Table 6](#T6){ref-type="table"}), two of them were classified as obese (H11, H18; BMI \>30.0) and two other were deemed as overweight (H17, H26; BMI 25.0--29.9). Similarly, two-third outliers in the Winnipeg healthy group ([Table 2](#T2){ref-type="table"}) were classified as overweight (BM0003, BM0004). Unfortunately for the one participant that was classified as obese (BM0006) and registered at CancerCare Manitoba, no clinically relevant information was available. Taken together, the amantadine test could be of value for assessing risk of cancer in overweight/obese individuals, a possibility that warrants future large trial in this area.

It should also be mentioned that we used different cutoff values for the basal AA concentration in the healthy adults in the Bangladesh versus Winnipeg cohorts. This may be as a consequence of geographical and environmental factors. Indeed, we have previously observed regional/ethnic differences in AA concentration in healthy adults \[[@B44]\] that may be a reflection of the influence of environmental, socioeconomic and lifestyle factors affecting the basal SSAT-1 activity. However, these factors remain incompletely understood warranting further investigation. In addition, while not recorded in the present study, in subsequent studies, family history of cancer should be documented as it is conceivable that the amantadine test may be detecting presymptomatic cancer in populations that may be genetically predisposed for cancer.

Current standards for determining and verifying the presence of cancer involve computed tomography, MRI and ultrasound in conjunction with molecular and protein biomarkers; however, their use is limited because of the challenges regarding costs, accessibility, exposure to ionizing radiation and levels of false-positive results. In addition, biopsies for cancer diagnosis are invasive, time consuming, distressing, expensive and cannot be performed repeatedly \[[@B10],[@B45]\]. Thus, the simple, noninvasive, no risk, painless and cost-effective amantadine test may become an alternative or supplementary assessment tool to identify and follow malignant disease. Furthermore, with this test there is no need for surgery and the potential to reduce diagnosis needs to be further examined.

Conclusion {#S0013}
==========

Analysis of the 'outliers' observed in previous studies using the amantadine test revealed that a large number were at risk or developed cancer, suggesting that the test can predict the occurrence of cancer. Monitoring of urinary AA concentration combined with clinical and hematological characteristics could be established as a useful tool for purposes of screening and follow-up for cancer in high-risk populations.

Future perspective {#S0014}
==================

Biomarkers that detect cancer and monitor response to treatment will be highly beneficial. Our findings in 'outliers' support usefulness of amantadine as a screening or surveillance test in populations considered at high risk for developing cancer. It is also possible that this test could be used for monitoring patients after curative surgical or chemoradiation therapy to assess eradication of the tumor. Also, in follow-up, it could possibly detect proliferation of new cancer cells (relapse).

###### Summary points

-   We have previously reported that increased spermidine/spermine N^1^-acetyltransferase activity is linked to cancer.

-   In the present study, a higher urinary concentrations of acetylamantadine were measured in some of the healthy adult volunteers at both study sites.

-   A follow-up of the outliers that entailed hematological assessments, mammogram, ultrasound as well as additional amantadine test was carried out with the Bangladesh group. A health questionnaire and access to electronic medical records was performed with the Winnipeg site outliers.

-   The follow-up data obtained at both sites are suggestive that the amantadine test may be detecting cancer cases prior to clinical symptoms.

-   The amantadine test could potentially serve as a novel, simple to use and low-cost early detection test for cancer or for surveillance in populations considered at high risk for cancer.

-   These possibilities warrant future large-scale studies.

**Author contributions**

DS Sitar, A Maksymiuk and RB Ahmed designed the study, were involved in reviewing the data analysis, contributed to writing the paper and had primary responsibility for final content as well as procuring financial support for the clinical studies. DS Sitar and A Maksymiuk were also responsible for the development of the overall research plan. A Maksymiuk provided medical oversight for the clinical study at the Canada site. PS Tappia was responsible for the enrollment and informed consent as well as implementation of the study at the Winnipeg site. He also wrote the initial draft of the paper. PS Akhtar provided medical oversight for the clinical study at the Bangladesh site. N Khatun, R Parveen, R Ahmed were responsible for regulatory approvals and study implementation at the Bangladesh site. B Cheng and DS Sitar were involved in the development of the LC--MS/MS assay for detection of acetylated amantadine. B Cheng also analyzed the data and performed the statistical analysis. H Bach and G Huang participated in the data analysis and writing of the manuscript. B Hiebert served as consultant biostatistician for analysis and interpretation of the data. B Ramjiawan provided the expertise for regulatory and institutional review board approvals and contributed to the design of the study. All the authors approved the manuscript.

**Financial & competing interests disclosure**

RB Ahmed is the President and CEO and B Cheng is the acting CTO of BioMark Diagnostics Inc. A Maksymiuk, DS Sitar, H Bach, PS Tappia and B Ramjiawan are minor shareholders of BioMark Diagnostics Inc. This study was supported, in part, by BioMark Diagnostics Inc. (BC, Canada) and the Maunders-McNeil Foundation (AB, Canada). LC--MS/MS analysis was conducted by Biopharmaceutical Research Inc. (BC, Canada). Infrastructural support was provided by the St Boniface Hospital Foundation and the University of Manitoba. Part of this work was published in abstract form in the 2019 ASCO meeting proceedings (online): https://meetinglibrary.asco.org/record/177214/abstract

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

**Ethical conduct of research**

The authors state that they have obtained appropriate institutional review board approvals and have followed the principles outlined in the Declaration of Helsinki for all human experimental investigations. In addition, informed consent has been obtained from the participants involved.

**Open access**

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

**Clinical trial data disclosure**

The authors certify that this manuscript reports original clinical trial data. The data will not be made publicly available.
